Vanguard Capital Management’s TransCode Therapeutics RNAZ Stock Holding History
Bought
Maintained
Sold
Other funds holding RNAZ
Vanguard Capital Management's RNAZ Position: Q3 2026 in Review
Vanguard Capital Management held its TransCode Therapeutics (RNAZ) position steady in Q3 2026 at 6,545 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #4013.
Vanguard Capital Management first reported a position in RNAZ in Q1 2026 and has held it in 3 quarters since. The position peaked at $56.4K in Q1 2026. 12 funds tracked by Wall St. Rank hold RNAZ as of Q3 2026.
- Vanguard Capital Management held 6,545 shares of TransCode Therapeutics worth $11K as of Q3 2026.
- Vanguard Capital Management left its TransCode Therapeutics share count unchanged in Q3 2026.
- TransCode Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #4013 holding.
- Vanguard Capital Management first reported a position in TransCode Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's TransCode Therapeutics position peaked at $56.4K in Q1 2026.
- 12 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.